3Derm Systems

3Derm Systems

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $18.7M

Overview

Founded in 2012 and based in New Haven, Connecticut, 3Derm Systems is a private company that created an integrated hardware and software platform for teledermatology. Its technology combines a proprietary skin imaging system with world-class machine learning algorithms designed to capture high-quality images and assist in diagnosing skin diseases, including skin cancer. The company has achieved significant regulatory milestones, including FDA Breakthrough Device designations for its autonomous skin cancer AI, and was acquired by Digital Diagnostics, a leader in autonomous AI diagnostics, to expand its reach and impact.

DermatologyOncology

Technology Platform

Proprietary skin imaging hardware combined with machine learning algorithms for remote capture, analysis, and diagnosis of skin lesions, including autonomous AI for skin cancer detection.

Funding History

3
Total raised:$18.7M
Series B$12M
Series A$5.5M
Seed$1.2M

Opportunities

The severe global shortage of dermatologists creates a massive need for scalable triage solutions.
The acquisition by Digital Diagnostics provides a clear regulatory roadmap, commercial infrastructure, and the potential to create a multi-specialty autonomous AI diagnostics platform, significantly accelerating market penetration.

Risk Factors

Achieving FDA clearance for autonomous dermatology AI is a major regulatory hurdle.
Competition from pure-software AI solutions using smartphone cameras is intense, and securing consistent insurance reimbursement for AI-driven diagnostics remains a critical challenge for sustainable commercialization.

Competitive Landscape

The AI dermatology space is highly competitive, including pure-software startups (e.g., MetaOptima, SkinVision), large tech companies (Google, IBM), and integrated device/AI companies. 3Derm's differentiation was its combined hardware-software approach for image quality. Post-acquisition, its primary competitive advantage is being part of the first company with an FDA-cleared autonomous AI, providing unique regulatory and commercial experience.